Silence Inks siRNA-Delivery Deal with Dainippon Sumitomo Pharma | GenomeWeb

Silence Therapeutics said last week that it has entered into an siRNA drug-delivery collaboration with Japanese drug firm Dainippon Sumitomo Pharma.

Under the terms of the deal, Silence will “demonstrate the functional delivery” of its proprietary siRNA molecules, in combination with its in-house AtuPlex delivery technology, to certain undisclosed targets.

Additional terms of the arrangement, including financial details, were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.